Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical Cancer

April 1, 2019
David S. Hong, MD

<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic&nbsp; or recurrent cervical cancer.</p>

David S. Hong, MD, deputy director of the department of investigational cancer therapeutics and associate vice president at The University of Texas MD Anderson Cancer Center, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.

The phase I study led to a recommended phase II dose of 2 mg/kg every 3 weeks, according to Hong. This dose showed activity across a number of histologies, but in particular, showed promising results in this patient population with cervical cancer.